North America Branded Generics Market Size & Outlook

The branded generics market in North America is expected to reach a projected revenue of US$ 68,874.5 million by 2030. A compound annual growth rate of 4.9% is expected of North America branded generics market from 2023 to 2030.
Revenue, 2022 (US$M)
$47,334.4
Forecast, 2030 (US$M)
$68,874.5
CAGR, 2023 - 2030
4.9%
Report Coverage
North America

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

North America branded generics market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

North America branded generics market highlights

  • The North America branded generics market generated a revenue of USD 47,334.4 million in 2022.
  • The market is expected to grow at a CAGR of 4.9% from 2023 to 2030.
  • In terms of segment, anti-hypertensive was the largest revenue generating drug class in 2022.
  • Hormones is the most lucrative drug class segment registering the fastest growth during the forecast period.
  • Country-wise, Canada is expected to register the highest CAGR from 2023 to 2030.


North America data book summary

Market revenue in 2022USD 47,334.4 million
Market revenue in 2030USD 68,874.5 million
Growth rate4.9% (CAGR from 2023 to 2030)
Largest segmentAnti-hypertensive
Fastest growing segmentHormones
Historical data covered2018 - 2021
Base year for estimation2022
Forecast period covered2023 - 2030
Quantitative unitsRevenue in USD million
Market segmentationAlkylating Agents, Antimetabolites, Hormones, Anti-hypertensive, Lipid Lowering drugs, Anti-depressants, Anti-psychotics, Anti-epileptics
Key market players worldwideTeva Pharmaceutical Industries Ltd, Lupin, Sanofi SA, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, GlaxoSmithKline, Pfizer Inc, Apotex Inc., Viatris Inc


Other key industry trends

  • In terms of revenue, North America region accounted for 19.7% of the global branded generics market in 2022.
  • Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 188,013.8 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Branded Generics Market Companies

Name Profile # Employees HQ Website
Apotex Inc. View profile 10001+ Toronto, Ontario, Canada, North America http://www.apotex.com
GlaxoSmithKline View profile 10001+ London, England, United Kingdom, Europe http://www.gsk.com
Viatris Inc View profile 38000 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 https://www.viatris.com
Dr. Reddy’s Laboratories View profile 10001+ Hyderabad, Andhra Pradesh, India, Asia http://www.drreddys.com/
Sun Pharmaceutical Industries View profile 10001+ Mumbai, Maharashtra, India, Asia http://www.sunpharma.com
Lupin View profile 10001+ Mumbai, Maharashtra, India, Asia https://www.lupin.com
Sanofi SA View profile 87994 46, avenue de la Grande Armée, Paris, France, 75017 https://www.sanofi.com
Pfizer Inc View profile 88000 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 https://www.pfizer.com
Teva Pharmaceutical Industries Ltd View profile 37851 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 https://www.tevapharm.com

North America branded generics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to branded generics market will help companies and investors design strategic landscapes.


Anti-hypertensive was the largest segment with a revenue share of 16.4% in 2022. Horizon Databook has segmented the North America branded generics market based on alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptics covering the revenue growth of each sub-segment from 2018 to 2030.


Growth of North America branded generic market can be attributed to various factors, such presence of major market players & well-developed infrastructure, rise in prevalence of various diseases in the region, and favorable government initiatives that support the uptake of branded generics.

Furthermore, increasing awareness pertaining to highly potent drugs, rising demand for anti-cancer therapeutics, and growing number of pharmaceutical companies are some of the factors contributing to the high share held by this regional market.

Increase in regulatory support and rise in investments in biotechnology & pharmaceutical industries are anticipated to fuel market growth. Moreover, blockbuster and patented drugs nearing expiration provide key opportunities to companies for revenue generation by manufacture and sale of branded generics.

Reasons to subscribe to North America branded generics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of North America branded generics market databook

  • Our clientele includes a mix of branded generics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the North America branded generics market , including forecasts for subscribers. This continent databook contains high-level insights into North America branded generics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

North America branded generics market size, by country, 2018-2030 (US$M)

North America Branded Generics Market Outlook Share, 2022 & 2030 (US$M)

North America branded generics market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online